The DOI matches its Crossref record; 46 of the 48 references it cites were found in a registry or an index.
Etoposide Selectively Ablates Activated T Cells To Control the Immunoregulatory Disorder Hemophagocytic Lymphohistiocytosis
Open accessAbstract
Hemophagocytic lymphohistiocytosis (HLH) is an inborn disorder of immune regulation caused by mutations affecting perforin-dependent cytotoxicity. Defects in this pathway impair negative feedback between cytotoxic lymphocytes and APCs, leading to prolonged and pathologic activation of T cells. Etoposide, a widely used chemotherapeutic drug that inhibits topoisomerase II, is the mainstay of treatment for HLH, although its therapeutic mechanism remains unknown. We used a murine model of HLH, involving lymphocytic choriomeningitis virus infection of perforin-deficient mice, to study the activity and mechanism of etoposide for treating HLH and found that it substantially alleviated all symptoms of murine HLH and allowed prolonged survival. This therapeutic effect was relatively unique among chemotherapeutic agents tested, suggesting distinctive effects on the immune response. We found that the therapeutic mechanism of etoposide in this model system involved potent deletion of activated T cells and efficient suppression of inflammatory cytokine production. This effect was remarkably selective; etoposide did not exert a direct anti-inflammatory effect on macrophages or dendritic cells, and it did not cause deletion of quiescent naive or memory T cells. Finally, etoposide’s immunomodulatory effects were similar in wild-type and perforin-deficient animals. Thus, etoposide treats HLH by selectively eliminating pathologic, activated T cells and may have usefulness as a novel immune modulator in a broad array of immunopathologic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cyclophosphamide and etoposide, which are broadly cytotoxic but particularly effective at eliminating activated CD8+ T cells, are often effective in patients with primary HLH, secondary HLH (including macrophage activation syndrome), and corresponding models.75”
From Cytokine storm (2020) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dose translation from animal to human studies revisited.
Reagan‐Shaw, S., Nihal, M., & Ahmad, N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9574lsf · Cited by 6,524
HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis
Henter, J., Horne, A., Aricò, M., Egeler, R. M., Filipovich, A. H., Imashuku, S., Ladisch, S., McClain, K. L., Webb, D. K. H., Winiarski, J. H., et al. (2006) · Pediatric Blood & Cancer · doi:10.1002/pbc.21039 · Cited by 5,396
How I treat hemophagocytic lymphohistiocytosis
Jordan, M. B., Allen, C. E., Weitzman, S. S., Filipovich, A. H., & McClain, K. L. (2011) · Blood · doi:10.1182/blood-2011-03-278127 · Cited by 1,145
Self-citationEtoposide: four decades of development of a topoisomerase II inhibitor
Hande, K. R. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00228-7 · Cited by 962
Henter, J. (2002) · Blood · doi:10.1182/blood-2002-01-0172 · Cited by 900
Ahmed, R., Salmi, A. A., Butler, L. D., Chiller, J. M., & Oldstone, M. B. A. (1984) · The Journal of Experimental Medicine · doi:10.1084/jem.160.2.521 · Cited by 792
Jordan, M. B., Hildeman, D., Kappler, J., & Marrack, P. (2004) · Blood · doi:10.1182/blood-2003-10-3413 · Cited by 712
Self-citationTrottestam, H., Horne, A., Aricò, M., Egeler, R. M., Filipovich, A. H., Gadner, H., Imashuku, S., Ladisch, S., Webb, D. K. H., Janka, G., et al. (2011) · Blood · doi:10.1182/blood-2011-06-356261 · Cited by 684
Familial hemophagocytic lymphohistiocytosis
Janka, G. (1983) · European Journal of Pediatrics · doi:10.1007/bf00443367 · Cited by 576
Crawford, F., Kozono, H., White, J., Marrack, P., & Kappler, J. W. (1998) · Immunity · doi:10.1016/s1074-7613(00)80572-5 · Cited by 459
Cited by
Sorted by citations
Fajgenbaum, D. C., & June, C. H. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2026131 · Cited by 3,196
Recommendations for the management of hemophagocytic lymphohistiocytosis in adults
Rosée, P. G. L., Horne, A., Hines, M., Greenwood, T. V. B., Machowicz, R., Berliner, N., Birndt, S., Gil-Herrera, J., Girschikofsky, M., Jordan, M. B., et al. (2019) · Blood · doi:10.1182/blood.2018894618 · Cited by 1,127
Self-citationCOVID-19: Transmission, prevention, and potential therapeutic opportunities
Lotfi, M., Hamblin, M. R., & Rezaei, N. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.05.044 · Cited by 1,065
Bergsten, E., Horne, A., Aricò, M., Astigarraga, I., Egeler, R. M., Filipovich, A. H., Ishii, E., Janka, G., Ladisch, S., Lehmberg, K., et al. (2017) · Blood · doi:10.1182/blood-2017-06-788349 · Cited by 677
Hemophagocytic syndromes — An update
Janka, G., & Lehmberg, K. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.03.002 · Cited by 461
Metadata
- Authors
- Johnson, T. S., Terrell, C. E., Millen, S. H., Katz, J. D., Hildeman, D. A., & Jordan, M. B.
- Affiliations
- Augusta University (US)
- Cincinnati Children's Hospital Medical Center (US)
- Corresponding author
- Jordan, Michael B
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-01-01
- Volume
- 192
- Issue
- 1
- Pages
- 84-91
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- PMC
- PMC4177106
- OpenAlex
- W2105957247
- Cited by
- 203
- References
- 48
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 29 · 2023: 19 · 2022: 17 · 2021: 20 · 2020: 28 · 2019: 18 · 2018: 12 · 2017: 19 · 2016: 8 · 2015: 8 · 2014: 4
- FWCI
- 5.02
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL091769)
- National Institute of Allergy and Infectious Diseases (U54AI082973)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK081175)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30AR047363)
- Topics
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Keywords
- hemophagocytic lymphohistiocytosis, etoposide, perforin deficiency, topoisomerase II inhibition, cytotoxic T lymphocytes, lymphocytic choriomeningitis virus, inflammatory cytokines, immunomodulation, innate immune regulation
- MeSH terms
- Animals, Dendritic Cells, Disease Models, Animal, DNA-Binding Proteins, Etoposide, Interferon-gamma, Lymphocyte Activation, Lymphocytic choriomeningitis virus, Macrophage Activation, Macrophages, T-Lymphocytes, Apoptosis, Antigen Presentation, Mice, Knockout, Lymphohistiocytosis, Hemophagocytic, Mice, Topoisomerase II Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
